The ?7 and ?4?2* ("*" denotes possibly assembly with another subunit) nicotinic acetylcholine receptors (nAChRs) are the most abundant nAChRs in the mammalian brain. These receptors are the most targeted nAChRs in drug discovery programmes for brain disorders. However, the development of subtype-specific agonists remains challenging due to the high degree of sequence homology and conservation of function in nAChRs. We have developed C(10) variants of cytisine, a partial agonist of ?4?2 nAChR that has been used for smoking cessation. The C(10) methyl analogue used in this study displays negligible affinity for ?7 nAChR, while retaining high affinity for ?4?2 nAChR. Experimental Approach: The structural underpinning of the selectivity of 10-methylcytisine for ?7 and ?4?2 nAChRs was investigated using molecular dynamic simulations, mutagenesis and whole-cell and single-channel current recordings. Key Results: We identified a conserved arginine in the ?3 strand that exhibits a nonconserved function in nAChRs. In ?4?2 nAChR, the arginine forms a salt bridge with an aspartate residue in loop B that is necessary for receptor expression, whereas in ?7 nAChR, this residue is not stabilised by electrostatic interactions, making its side chain highly mobile. This lack of constrain produces steric clashes with agonists and affects the dynamics of residues involved in agonist binding and the coupling network. Conclusion and Implications: We conclude that the high mobility of the ?3-strand arginine in the ?7 nAChR influences agonist binding and possibly gating network and desensitisation. The findings have implications for rational design of subtypeselective nAChR agents

A conserved arginine with non-conserved function is a key determinant of agonist selectivity in alpha7 nicotinic ACh receptors.

Gotti C;
2021

Abstract

The ?7 and ?4?2* ("*" denotes possibly assembly with another subunit) nicotinic acetylcholine receptors (nAChRs) are the most abundant nAChRs in the mammalian brain. These receptors are the most targeted nAChRs in drug discovery programmes for brain disorders. However, the development of subtype-specific agonists remains challenging due to the high degree of sequence homology and conservation of function in nAChRs. We have developed C(10) variants of cytisine, a partial agonist of ?4?2 nAChR that has been used for smoking cessation. The C(10) methyl analogue used in this study displays negligible affinity for ?7 nAChR, while retaining high affinity for ?4?2 nAChR. Experimental Approach: The structural underpinning of the selectivity of 10-methylcytisine for ?7 and ?4?2 nAChRs was investigated using molecular dynamic simulations, mutagenesis and whole-cell and single-channel current recordings. Key Results: We identified a conserved arginine in the ?3 strand that exhibits a nonconserved function in nAChRs. In ?4?2 nAChR, the arginine forms a salt bridge with an aspartate residue in loop B that is necessary for receptor expression, whereas in ?7 nAChR, this residue is not stabilised by electrostatic interactions, making its side chain highly mobile. This lack of constrain produces steric clashes with agonists and affects the dynamics of residues involved in agonist binding and the coupling network. Conclusion and Implications: We conclude that the high mobility of the ?3-strand arginine in the ?7 nAChR influences agonist binding and possibly gating network and desensitisation. The findings have implications for rational design of subtypeselective nAChR agents
2021
agonist selectivity
C(10) cytisine derivatives
cytisine
nicotinic ACh receptors
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/446996
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact